Business Context and Reporting Period
Company: Adtalem Global Education Inc. (Note: Input metadata referenced "Covista Inc.", but the filing text identifies the registrant as Adtalem Global Education Inc., trading as ATGE).
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Second quarter of fiscal year 2026, ended December 31, 2025.
Business Overview: Adtalem is a leading healthcare educator in the U.S. operating three reportable segments: Chamberlain University (nursing/health professions), Walden University (graduate/professional degrees), and Medical and Veterinary schools (AUC, RUSM, RUSVM).
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Revenue | $503.4 million | $965.7 million |
| Operating Income | $111.1 million | $196.6 million |
| Net Income | $76.4 million | $138.2 million |
| Diluted EPS | $2.11 | $3.77 |
| Operating Cash Flow (Continuing Ops) | N/A | $160.1 million |
| Cash and Cash Equivalents | $56.3 million (Dec 31, 2025) | $56.3 million (Dec 31, 2025) |
| Long-Term Debt | $504.3 million | $504.3 million |
| Share Repurchases | 1.73 million shares ($164.9 million) | 1.78 million shares ($172.5 million) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 12.4% ($55.7 million) in Q2 and 11.6% ($100.5 million) for the six months ended Dec 31, 2025, compared to the prior year. Growth was driven by all segments, with Walden showing the strongest increase (27.0% in Q2).
- Profitability: Net income increased slightly by 0.7% in Q2. However, Adjusted Net Income (non-GAAP) increased 26.7% to $87.9 million, driven by revenue growth and lower interest expense, partially offset by higher strategic advisory costs and labor expenses.
- Segment Performance:
- Walden: Adjusted operating income surged 70.0% due to enrollment growth and higher tuition rates.
- Chamberlain: Adjusted operating income decreased 20.0% due to increased labor and marketing costs, despite a 1.6% revenue increase.
- Medical & Veterinary: Adjusted operating income increased 16.3% driven by enrollment and tuition rate increases.
- Restructuring: Restructuring expense increased significantly to $4.1 million in Q2 (vs. $0.3 million prior year) primarily due to workforce reductions.
- Interest Expense: Decreased to $10.9 million in Q2 (vs. $13.9 million prior year) due to lower Term Loan B balances and interest rates.
Guidance, Outlook, and Risks
- Regulatory Environment (OBBBA): The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 introduces substantial changes to federal student aid, including increased loan limits for professional programs but the eventual phase-out of Grad PLUS loans. The impact on Adtalem is not yet fully known as regulations are pending.
- Financial Responsibility: Adtalem's composite score for Title IV eligibility remains below 1.5 (0.2 in FY2022), requiring provisional certification and the maintenance of $202.6 million in letters of credit. Management does not believe this materially affects operations.
- Borrower Defense to Repayment (BDR): Institutions have received thousands of BDR claims. To date, no claims have been approved, and no recoupment notices have been received.
- Capital Allocation: The Board authorized a new $750 million share repurchase program (16th program) in December 2025. As of Dec 31, 2025, $727.5 million remained available.
- Enrollment Trends: Walden enrollment increased 13.0% year-over-year. Chamberlain enrollment decreased 1.0% in the November 2025 session. Medical and Veterinary enrollment increased 2.4%.
Investor Verification Checklist
- Regulatory Impact: Monitor the implementation of OBBBA regulations and their specific effect on Grad PLUS loan availability and Title IV eligibility for Adtalem's programs.
- Chamberlain Margins: Verify if the decline in Chamberlain's adjusted operating income margin is a temporary result of investment cycles or a structural shift in the nursing education market.
- Liquidity Position: Review the cash burn rate relative to the $56.3 million cash balance and the $500 million revolver availability, especially given the significant share repurchase activity ($172.5 million in six months).
- BDR Exposure: Track the status of the 14,000+ Borrower Defense to Repayment claims received across institutions to assess potential future liability.
- Debt Covenants: Confirm continued compliance with the Total Net Leverage Ratio covenant (max 3.25:1) as debt levels and earnings fluctuate.